Original Article

You have full text access to this OnlineOpen article

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

  1. Caroline Laverdiere M.D.1,
  2. E. Anders Kolb M.D.1,
  3. Jeffrey G. Supko Ph.D.2,
  4. Richard Gorlick M.D.1,†,*,
  5. Paul A. Meyers M.D.1,
  6. Robert G. Maki M.D.3,‡,
  7. Leonard Wexler M.D.1,
  8. George D. Demetri M.D.2,§,
  9. John H. Healey M.D.4,
  10. Andrew G. Huvos M.D.5,
  11. Allen M. Goorin M.D.2,
  12. Rochelle Bagatell M.D.6,
  13. Ana Ruiz-Casado M.D.7,¶,
  14. Cecilia Guzman M.D.7,‖,
  15. Jose Jimeno M.D.7,††,
  16. David Harmon M.D.2

Article first published online: 12 JUN 2003

DOI: 10.1002/cncr.11563

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 832–840, 15 August 2003

Additional Information

How to Cite

Laverdiere, C., Kolb, E. A., Supko, J. G., Gorlick, R., Meyers, P. A., Maki, R. G., Wexler, L., Demetri, G. D., Healey, J. H., Huvos, A. G., Goorin, A. M., Bagatell, R., Ruiz-Casado, A., Guzman, C., Jimeno, J. and Harmon, D. (2003), Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer, 98: 832–840. doi: 10.1002/cncr.11563

Author Information

  1. 1

    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    Division of Hematology Oncology, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts

  3. 3

    Division of Medical Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

  4. 4

    Division of Orthopedic Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

  5. 5

    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York

  6. 6

    Department of Pediatrics, University of Arizona Health Sciences Center, Tucson, Arizona

  7. 7

    PharmaMar S. A., Tres Cantos, Spain

  1. †

    Fax: (212) 717-3239

  2. ‡

    Robert G. Maki, M.D., received funding to research studies from PharmaMar, Inc. and the National Cancer Institute (NCI Program Project Grant P01-CA47179).

  3. §

    George D. Demetri, M.D., received support for research and consulting (within acceptable Harvard conflict of interest rules) from corporate entities that currently are developing ET-743 (PharmaMar and Johnson & Johnson).

  4. Ana Ruiz-Casado, M.D., is employed as a medical oncologist for PharmaMar S. A.

  5. ‖

    Cecilia Guzman, M.D., was a full-time employee of PharmaMar S. A. during the course of the current study.

  6. ††

    Jose Jimeno, M.D., is Vice President of Scientific Development for PharmaMar S. A. and is a stockholder in the company.

*Department of Pediatrics, Howard Building 11th Floor, Room 1110, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 12 JUN 2003
  3. Manuscript Accepted: 5 MAY 2003
  4. Manuscript Revised: 29 APR 2003
  5. Manuscript Received: 25 FEB 2003

Funded by

  • PharmaMar S. A., Tres Cantos, Spain

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (108K)

REFERENCES

  • 1
    Link MP, Gebhardt MC, Meyers PA. Osteosarcoma. In: PizzoPA, PoplackDG, editors. Principles and practice of pediatric oncology, 4th edition. Philadelphia: Lippincott Williams & Wilkins, 2002: 1051–1090.
  • 2
    Pastorino U, Gasparini M, Tavecchio L, et al. The contribution of salvage surgery to the management of childhood osteosarcoma. J Clin Oncol. 1991; 9: 1357–1362.
  • 3
    Tabone MD, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 1994; 12: 2614–2620.
  • 4
    Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer. 1995; 75: 1084–1093.
    Direct Link:
  • 5
    Gentet JC, Bruant-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer. 1997; 33: 232–237.
  • 6
    Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol. 1997; 8: 765–771.
  • 7
    Michelagnoli MP, Lewis IJ, Gattamaneni HR, et al. Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma. Br J Cancer. 1999; 79: 1174–1178.
  • 8
    Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian Sarcoma Group Study. J Clin Oncol. 2002; 20: 2150–2156.
  • 9
    Rodriguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol. 2002; 24: 250–255.
  • 10
    Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group trial. J Clin Oncol. 2002; 20: 426–433.
  • 11
    Rinehart KL, Holt TG, Fregeau NL, et al. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean Tunicate Ecteinascidia turbinata. J Org Chem. 1990; 55: 4512–4515.
  • 12
    Jimeno J, Faircloth G, Cameron L, et al. Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743). Drugs Future. 1996; 21: 1155–1165.
  • 13
    Sakai R, Rinehart KL, Guan Y, et al. Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proc Natl Acad Sci U S A. 1992; 89: 11456–11460.
  • 14
    Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol. 1998; 9: 981–987.
  • 15
    Hendricks HR, Fiebig HH, Giavazzi R, et al. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol. 1999; 10: 1233–1240.
  • 16
    Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res. 2001; 7: 2908–2911.
  • 17
    Scotlandi K, Perdichizzi S, Manara MC, et al. Effectiveness of Ecteinascidin-743 against drug-sensitive and –resistant bone tumor cells. Clin Cancer Res. 2002; 8: 3893–3903.
  • 18
    Ghielmini M, Colli E, Erba E, et al. In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). Ann Oncol. 1998; 9: 989–993.
  • 19
    Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res. 2001; 7: 3251–3257.
  • 20
    Pommier Y, Kohlhagen G, Bailly C, et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996; 35: 13303–13309.
  • 21
    Moore BM, Seaman FC, Wheelhouse RT, et al. Mechanism for the catalytic activation of Ecteinascidin 743 and its subsequent alkylation of guanine N2. J Am Chem Soc. 1998; 120: 2490–2491.
  • 22
    Seaman FC, Hurley LH. Molecular basis for the DNA sequence selectivity of Ecteinascidin 736 and 743: evidence for the dominant role of direct readout via hydrogen bonding. J Am Chem Soc. 1998; 120: 13028–13041.
  • 23
    Takebayashi Y, Pourquier P, Yoshida A, et al. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci U S A. 1999; 96: 7196–7201.
  • 24
    Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem. 1999; 42: 2493–2497.
  • 25
    Bonfanti M, La Valle E, Fernandez Sousa Faro J-M, et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. 1999; 14: 179–186.
  • 26
    Jin S, Gorfajn B, Faircloth G, et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A. 2000; 97: 6775–6779.
  • 27
    Minuzzo M, Marchini S, Broggini M, et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A. 2000; 97: 6780–6784.
  • 28
    Garcia-Nieto R, Manzanares I, Cuevas C, et al. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions? J Med Chem. 2000; 43: 4367–4369.
  • 29
    Friedman D, Hu Z, Kolb EA, et al. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 2002; 62: 3377–3381.
  • 30
    Takebayashi Y, Goldwasser F, Urasaki Y, et al. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res. 2001; 7: 185–191.
  • 31
    Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of Ecteinascidin-743 in cancer cells. J Biol Chem. 2002; 44: 41580–41589.
  • 32
    Garcia-Rocha M, Garcia-Gravalos MD, Avila J. Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Br J Cancer. 1996; 73: 875–883.
  • 33
    Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001; 7: 961–966.
  • 34
    Zewail-Foote M, Li VS, Kohn H, et al. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol. 2001; 8: 1033–1049.
  • 35
    Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001; 37: 97–105.
  • 36
    D'Incalci M, Erba E, Damia G, et al. Unique features of the mode of action of ET-743. Oncologist. 2002; 7: 210–216.
  • 37
    D'Incalci M, Colombo T, Giavazzi G, et al. In human tumor xenografts the resistance to ET-743 or to cisplatin can be overcome by giving the two drugs in combination [abstract]. Eur J Cancer. 2002; 38 (Suppl 7): S34.
  • 38
    Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001; 19: 1256–1265.
  • 39
    Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001; 7: 231–242.
  • 40
    Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002; 8: 75–85.
  • 41
    Twelves C, Misset JL, Villalona-Calero M, et al. Phase I trials with ET-743, a marine derived (MD) anticancer agent[abstract 1135]. Presented at European Cancer Conference, Vienna, Austria; September 12–16, 1999.
  • 42
    Demetri GD, Manola J, Harmon D, et al. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): final results of phase II and pharmacokinetic studies in the U.S.A [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 352a.
  • 43
    Delaloge S, Yovine A, Taamma A, et al. Preliminary evidence of activity of ecteinascidin (ET-743) in heavily pretreated patients with bone and soft tissue sarcomas (STS) [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 554a.
  • 44
    Le Cesne A, Blay J-Y, Judson I, et al. ET-743 is an active drug in adult soft-tissue sarcoma: a STBSG-EORTC Phase II trial [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 353a.
  • 45
    George S, Maki RG, Harmon D, et al. Phase II study of ecteinascidin-743 (ET-743) given by 3-hour IV infusion in patients with soft tissue sarcomas failing prior chemotherapies [abstract]. Proc Am Soc Clin Oncol 2002; 21: 408a.
  • 46
    Dileo P, Casali PG, Bacci G, et al. Phase II evaluation of 3-hr infusion ET-743 in patients with recurrent sarcomas [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 408a.
  • 47
    Ruiz-Casado A, Lopez-Martin JA, Nieto A, et al. Ecteinascidin in heavily pretreated advanced sarcoma patients as a compassionate basis [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 408a.
  • 48
    World Health Organization. Handbook for reporting results of cancer treatment. World Health Organization Offset Pub. No. 48. Geneva: World Health Organization, 1979.
  • 49
    Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-hour continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol. 2002; 50: 309–319.
  • 50
    Casanova M, Casali PG, Sessa C, et al. Phase II study of 3-hour infusion of ET-743 in pretreated adult and pediatric patients with advanced/recurrent sarcomas – preliminary results from the Sendo and Italian Sarcoma Group [abstract O154]. Med Pediatr Oncol. 2002; 39: 257.
  • 51
    Baruchel S, Blaney S, Hershon L, et al. A phase 1 study of ET-743 in pediatric refractory solid tumors: a Children's Oncology Group study [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 96a.
  • 52
    Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995; 24: 87–92.
    Direct Link:
  • 53
    Gomez J, Lopez Lazaro L, Guzman C, et al. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743 [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 187a.
  • 54
    Lopez-Martin JA, Nieto A, Demetri GD, et al. Safety profile of ecteinascidin-743 (ET-743) in phase II clinical trials in adult patients with solid tumors [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 96a.
  • 55
    Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001; 7: 584–590.
  • 56
    Riccardi R, Colombo T, Meco D, et al. Effective combinations of ET-743 and doxorubicin for tumor growth inhibitions against murine and human sarcomas in athymic mice [abstract]. Proc Am Assoc Cancer Res. 2001; 42: 211.
  • 57
    Kanzaki A, Takebayashi Y, Ren XQ, et al. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther. 2002; 1: 1327–1334.
  • 58
    D'Incalci M, Erba E, Damia G, et al. The combination of ET-743 and cisplatin (DDP): from a molecular pharmacology study to a phase I clinical trial [abstract]. Proc Am Assoc Cancer Res. 2002; 43: 80.
  • 59
    Chabner BA. Cytotoxic agents in the era of molecular targets and genomics. Oncologist. 2002; 7 (Suppl 3): 34–41.
  • 60
    Faircloth GT, Grant W, Jimeno J, et al. Dexamethasone potentiates the activity of Ecteinascidin 743 in preclinical melanoma and osteosarcoma models [abstract]. Proc Am Assoc Cancer Res. 2002; 43: 75.
View Full Article (HTML) Get PDF (108K)